Methylphenidate Treatment of Cancer-Related Fatigue (EMF)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00758407
Recruitment Status : Completed
First Posted : September 25, 2008
Last Update Posted : January 13, 2010
Information provided by:
Medice Arzneimittel Pütter GmbH & Co KG

Brief Summary:
The purpose of this randomized controlled clinical trial is to investigate the efficacy and safety of methylphenidate in patients with fatigue caused by cancer.

Condition or disease Intervention/treatment Phase
Cancer-related Fatigue Drug: Methylphenidate hydrochloride Drug: Placebo Phase 2 Phase 3

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 66 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Placebo Controlled Double Blind Study With Methylphenidate in Treatment of Adults With Cancer-Related Fatigue
Study Start Date : August 2006
Actual Primary Completion Date : January 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Fatigue
U.S. FDA Resources

Arm Intervention/treatment
Active Comparator: 1 Drug: Methylphenidate hydrochloride
sustained release, dosage according to an individual titration schedule
Placebo Comparator: 2 Drug: Placebo
dosage according to an individual titration schedule

Primary Outcome Measures :
  1. General Fatigue measured by the Multidimensional Fatigue Inventory (Subscale General Fatigue) [ Time Frame: 6 weeks ]

Secondary Outcome Measures :
  1. Quality of Life (EORTC-QLQ C30) [ Time Frame: 6 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • history of Cancer
  • MFI >40
  • Karnofsky Index >=70
  • outpatient
  • patient are able to give informed consent

Exclusion Criteria:

  • treatment with psychostimulants in the past two weeks before screening
  • active tumor disease
  • depression (HADS >10)
  • cachexia (BMI <18kg/m2)
  • clinically relevant kidney disorders
  • clinically relevant liver disorder
  • pathological ECG-finding
  • high blood pressure
  • occlusive arterial disease
  • angina pectoris
  • cardiac arrhythmias
  • CHD
  • post heart-attack status
  • post stroke status
  • known elevated intra-ocular pressure
  • known enlarged prostates
  • latent and manifest hyperthyreosis
  • alcohol, medication or drug dependency in the past six months or manifest drug abuse
  • participation in a clinical study within the past 30 days
  • participation in this study at an earlier point in time
  • simultaneous participation in another clinical trial
  • women of child-bearing age without adequate contraception (contraceptives, intrauterine device , no sexual intercourse)
  • pregnancy (positive pregnancy test) or lactation period

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00758407

Bad Sooden-Allendorf, Germany
Praxis Dr. Lathan
Dortmund, Germany
Praxis Dr. Verpoort - Dr. Zeller
Hamburg, Germany
Dr. J.-U. Rüffer
Köln, Germany
Medizinische Fakultät der Universität Leipzig
Leipzig, Germany
Medizinisches Versorgungszentrum - MOP
München, Germany
Sponsors and Collaborators
Medice Arzneimittel Pütter GmbH & Co KG
Principal Investigator: Manfred Heim, Prof. Sonnenbergklinik, Hardstr. 13, D-37242 Bad Sooden-Allendorf

Responsible Party: Dr. Armin Engels, Medical Advisor, Medice Arzneimittel Pütter GmbH & Co KG Identifier: NCT00758407     History of Changes
Other Study ID Numbers: 6520-9959-02
First Posted: September 25, 2008    Key Record Dates
Last Update Posted: January 13, 2010
Last Verified: January 2010

Keywords provided by Medice Arzneimittel Pütter GmbH & Co KG:
Fatigue, Cancer, Methylphenidate,

Additional relevant MeSH terms:
Signs and Symptoms
Central Nervous System Stimulants
Physiological Effects of Drugs
Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Dopamine Agents
Neurotransmitter Agents